How Trixeo and 21GRAMS Made Judgment the Heart of a Healthcare Campaign
Trixeo's 'Judgy' campaign is a 2024 United Kingdom integrated healthcare campaign created by agency 21GRAMS that uses unscripted real-world footage of people judging one another to challenge the stigma and emotional barriers faced by individuals living with COPD, positioning the brand as an empathetic and accessible respiratory treatment, according to Pmsociety Org Uk.
Published in January 2024, 'Judgy' marks a deliberate tonal shift for Trixeo Aerosphere, AstraZeneca's fixed-dose inhaled triple therapy for moderate-to-severe COPD. Where the brand's earlier UK promotional materials, dating to its 2021 launch as reported by the Prescription Medicines Code of Practice Authority, leaned into clinical confidence through imagery of a small dragon exhaling three flames representing the product's three active pharmacotherapies, 'Judgy' moves the creative register firmly toward emotional resonance, according to Prod1 Warc. The campaign's core proposition targets the lived experience of patients who feel scrutinised or misunderstood because of their condition, framing treatment not as a clinical intervention but as a form of support.
The integrated campaign, developed by 21GRAMS and archived on Clapboard with a score of 58 out of 100, contains a single primary media asset: a film in which a voiceover delivered by a man with severe COPD accompanies scenes of people judging one another in everyday settings, according to En Wikipedia. The campaign operates across the United Kingdom healthcare market, engaging both patients and the healthcare professionals who influence prescribing decisions. By grounding its narrative in social judgment rather than clinical data, 'Judgy' attempts to reduce the emotional distance between a pharmaceutical brand and the people it exists to serve.
Trixeo's 'Judgy' campaign is built on a documented insight that stigma constitutes a genuine barrier to respiratory care engagement in the United Kingdom. Patients managing chronic obstructive pulmonary disease frequently report feeling judged, whether for the condition itself, its association with smoking, or the visible act of using an inhaler in public. 21GRAMS identified this emotional friction as the strategic entry point for the campaign, constructing a narrative that validates the patient's social experience before introducing the brand's clinical proposition.
The United Kingdom respiratory therapeutics market is competitive and growing. Trixeo Aerosphere competes in the single-inhaler triple-therapy segment alongside GlaxoSmithKline's Trelegy Ellipta, a rival fixed-dose combination inhaler that has commanded significant prescriber attention since its own UK launch. The competitive pressure to differentiate on emotional territory rather than clinical specification alone reflects a broader strategic logic: in a segment where pharmacological profiles are closely matched, patient trust and brand empathy become meaningful differentiators. The global COPD and asthma therapeutics market was estimated at a substantial scale in 2024, according to Mordor Intelligence, with continued growth projected through 2030, underscoring the commercial stakes attached to brand positioning decisions in this category.
21GRAMS chose narrative over data as the campaign's organising principle. Rather than leading with the triple-therapy mechanism or exacerbation-reduction data that characterised earlier Trixeo materials, as documented by the Prescription Medicines Code of Practice Authority, 'Judgy' places patient psychology at the centre of communication. This approach reflects a maturation in pharmaceutical advertising across the United Kingdom, where regulatory frameworks still shape what can be claimed directly to consumers but leave room for emotionally intelligent brand storytelling aimed at healthcare professionals and patient-facing contexts alike.
The creative execution of 'Judgy' rests on a single, defining production decision: the campaign used only real people rather than experienced actors. This commitment to authenticity shaped every dimension of the film's visual and emotional register, from the texture of individual performances to the raw incidents that occurred during filming itself.
Production credits for 'Judgy' are not fully publicly documented in trade press records. However, Clapboard's archive records that the creative team at 21GRAMS described their directorial approach as voyeuristic, framing the camera as a witness to moments so personal and unguarded that they carry genuine weight for both the person being judged and the observer. This aesthetic sensibility — peeking in rather than staging — aligns with a broader movement in healthcare advertising toward documentary-influenced realism, where the absence of polish becomes evidence of sincerity.
The production process generated at least one incident that speaks to the lived reality the campaign sought to capture. During filming of a scene depicting a couple kissing in a public setting in the United Kingdom, two separate drivers shouted slurs at them before speeding away, as documented in the Clapboard archive. Rather than treating this as an obstacle, the creative team appears to have understood such moments as confirmation of the social judgment the campaign was designed to address. The voiceover, delivered by a man with severe COPD, runs over these scenes of everyday judgment, creating a structural parallel between stigma experienced in public life and stigma experienced as a patient. The campaign was submitted for consideration at the D&AD Awards in 2024, as recorded by Clapboard. Separately, 21GRAMS received a PM Society Awards 2025 Silver in the Product Promotion Single Piece category and a PM Society Awards 2025 Finalist position in Film Craft, both for work produced for AstraZeneca, according to the PM Society.
No independently verified performance data specific to the 'Judgy' campaign's commercial or clinical impact is publicly available. The Clapboard archive records 562 views, zero likes, and zero comments for the campaign listing, and no coverage from trade publications including Campaign, The Drum, Adweek, or Contagious has been identified. The campaign has not generated documented discussion on social platforms including LinkedIn, YouTube, or Reddit.
The Clapboard Score for 'Judgy' is 58 out of 100. That figure reflects the platform's editorial assessment of the campaign's archival and creative standing relative to comparable work, and should be read as a benchmark rather than a performance metric.
Structurally, the campaign's single-asset format and its reliance on emotional narrative rather than measurable call-to-action mechanics make direct response attribution unlikely by design. Pharmaceutical integrated campaigns of this type in the United Kingdom are more commonly evaluated against prescriber awareness, patient-reported attitude shifts, and healthcare professional engagement metrics — none of which are available in the public domain for this work. What the creative architecture does demonstrate is disciplined strategic focus: one film, one insight, one emotional truth, delivered through a production approach that prioritised authenticity over production value. Whether that focus translated into measurable brand equity for Trixeo Aerosphere in the United Kingdom remains unverifiable from available public sources, though the agency's subsequent recognition at the PM Society Awards 2025 for related AstraZeneca work, as reported by the PM Society, suggests continued confidence in 21GRAMS' approach to the category.
Trixeo's 'Judgy' is a 2024 United Kingdom integrated healthcare campaign created by 21GRAMS for AstraZeneca's fixed-dose COPD inhaler Trixeo Aerosphere. The campaign uses a film featuring real people in unscripted moments of social judgment, narrated by a man with severe COPD, to challenge stigma around respiratory conditions and reposition the brand as empathetic.
21GRAMS created the Trixeo 'Judgy' campaign. The agency developed the integrated campaign for the United Kingdom market, publishing it in January 2024. 21GRAMS subsequently received a PM Society Awards 2025 Silver and a Finalist recognition in Film Craft for related AstraZeneca work, according to the PM Society.
The 21GRAMS creative team made a deliberate decision to cast only real people, not experienced actors, in the Trixeo 'Judgy' film. This choice supported a voyeuristic, documentary-style approach designed to capture unguarded, authentic reactions, reinforcing the campaign's core message about the genuine social stigma faced by COPD patients in the United Kingdom.
The Trixeo 'Judgy' campaign received a Clapboard Score of 58 out of 100. This score reflects Clapboard's editorial assessment of the campaign's archival and creative standing and is not an industry award. The campaign's archive listing recorded 562 views and no likes or comments at the time of review.
Trixeo launched in the United Kingdom in early 2021 with materials directed at healthcare professionals, including a campaign featuring a dragon exhaling three flames, as documented by the Prescription Medicines Code of Practice Authority. 'Judgy' represents a significant creative shift, moving from clinical imagery toward patient-centred emotional narrative under 21GRAMS' direction in 2024.
Trixeo Aerosphere competes primarily with GlaxoSmithKline's Trelegy Ellipta in the United Kingdom single-inhaler triple-therapy segment for moderate-to-severe COPD. Both products are fixed-dose combination inhalers with comparable pharmacological profiles, making brand differentiation through emotional and narrative advertising, as demonstrated by the 'Judgy' campaign, a strategically significant choice.
.webp)
Creative Collaboration Platform: The Backbone of Modern Creative WorkWhat is a creative collaboration platform?Clapboard defines a creative collaboration platform as the operational core for today’s distributed creative teams. This is not a collection of digital collaboration tools stitched together; Clapboard’s system
Understanding the Creative Production MarketplaceWhat is a Creative Production Marketplace?Clapboard defines a creative production marketplace as a structured ecosystem where brands, agencies, and production talent converge to execute video, advertising, and branded content at scale. Unlike the legacy agency or freelanREAD FULL ARTICLE
The Urgent Need for a Creative Production Operating SystemWhy Traditional Creative Production Models Break DownClapboard sees the creative production landscape shifting under pressure. Content velocity is no longer a buzzword—it’s a mandate. Modern advertising demands relentless output across dozens of channels, each wREAD FULL ARTICLE
